Yoshimura A, Yoshioka K, Hino M, Sugawara H, Sakato M, Endoh M
Research Laboratory, Zenyaku Kogyo Co. Ltd., Tokyo, Japan.
Arzneimittelforschung. 1999 May;49(5):420-6. doi: 10.1055/s-0031-1300437.
Influence of 4,5-dihydro-6-[1-[2-hydroxy-2-(4-cyanophenyl)ethyl]- 1,2,5,6,-tetrahydropyrido-4-yl]pyridazin-3(2H)-one (SCH00013) and vesnarinone (CAS 81840-15-5) on the arrhythmia experimentally induced by three different methods was investigated in dogs. In digitalis-induced arrhythmia, SCH00013 (3 mg/kg i.v.) showed a tendency to improve the arrhythmia with a decrease in the arrhythmic ratio and an increase in the conducted beats (CB), though these changes did not reach a significant level; it decreased significantly the blood pressure (BP) with no change in the total heart rate (THR) and atrial rate (AR). Vesnarinone (3 mg/kg i.v.) did not affect these parameters except for BP that was decreased significantly. In two-stage coronary ligation-induced arrhythmia, SCH00013 (1 and 3 mg/kg i.v.) did not change the arrhythmic ratio, CB, AR and BP, while the THR being slightly decreased; the arrhythmic ratio showed a tendency to decrease with SCH00013 when examined at 24 h after coronary ligation. Vesnarinone (3 mg/kg i.v.) did not affect these parameters at 24 and 48 h after ligation. In epinephrine (adrenaline)-induced arrhythmia, both SCH00013 and vesnarinone showed exacerbation of arrhythmia. SCH00013 at 1 mg/kg i.v. did not elicit ventricular fibrillation (VF) in five dogs examined, but at 3 mg/kg i.v. it elicited VF in two of three dogs. Vesnarinone at 1 mg/kg i.v. induced VF in all of three dogs examined. Incidence of VF induced by optical isomers of SCH00013 was not significantly different from each other: both isomers elicited VF in two of six dogs at 1 mg/kg i.v. and at 3 mg/kg i.v. each of them induced VF in two dogs examined. The present results indicate that SCH00013 is a cardiotonic agent that is equivalent to or less arrhythmogenic than vesnarinone in animal models of arrhythmia, such as adrenaline- and digitalis-induced arrhythmia and the two-stage coronary ligation-induced arrhythmia. Optical isomers of SCH00013 were essentially equieffective in eliciting exacerbation of adrenaline-induced arrhythmia in the dog.
研究了4,5 - 二氢 - 6 - [1 - [2 - 羟基 - 2 - (4 - 氰基苯基)乙基] - 1,2,5,6 - 四氢吡啶并 - 4 - 基]哒嗪 - 3(2H) - 酮(SCH00013)和维司力农(CAS 81840 - 15 - 5)对犬实验性诱导的三种不同心律失常的影响。在洋地黄诱导的心律失常中,SCH00013(静脉注射3mg/kg)显示出改善心律失常的趋势,心律失常比率降低,传导搏动(CB)增加,尽管这些变化未达到显著水平;它显著降低血压(BP),总心率(THR)和心房率(AR)无变化。维司力农(静脉注射3mg/kg)除显著降低的BP外,对这些参数无影响。在两阶段冠状动脉结扎诱导的心律失常中,SCH00013(静脉注射1和3mg/kg)未改变心律失常比率、CB、AR和BP,而THR略有降低;冠状动脉结扎后24小时检查时,SCH00013使心律失常比率有降低趋势。维司力农(静脉注射3mg/kg)在结扎后24小时和48小时对这些参数无影响。在肾上腺素诱导的心律失常中,SCH00013和维司力农均使心律失常加重。静脉注射1mg/kg的SCH00013在检查的5只犬中未诱发室颤(VF),但静脉注射3mg/kg时,3只犬中有2只诱发VF。静脉注射1mg/kg的维司力农在检查的3只犬中均诱发VF。SCH00013的旋光异构体诱导VF的发生率彼此无显著差异:两种异构体在静脉注射1mg/kg时,6只犬中有2只诱发VF,静脉注射3mg/kg时,检查的犬中有2只诱发VF。目前的结果表明,在心律失常动物模型中,如肾上腺素和洋地黄诱导的心律失常以及两阶段冠状动脉结扎诱导的心律失常,SCH00013是一种强心剂,其致心律失常作用等同于或小于维司力农。SCH00013的旋光异构体在加剧犬肾上腺素诱导的心律失常方面基本等效。